Padcev 30 mg Powder for concentrate for solution for infusion Vial
Product Overview
Padcev 30 mg Powder for concentrate for solution for infusion is a specialized medication designed for the treatment of certain types of cancer.
It is a targeted therapy specifically indicated for adult patients with locally advanced or metastatic urothelial cancer (a type of bladder cancer) who have previously received treatment with a PD-1/L1 inhibitor and platinum-containing chemotherapy.
This medication contains the active ingredient enfortumab vedotin, an antibody-drug conjugate that targets Nectin-4, a protein commonly found on urothelial cancer cells.
The powder must be reconstituted and diluted by a healthcare professional before being administered as an intravenous infusion.
Benefits of Use
Padcev offers a significant treatment option for patients facing advanced urothelial cancer after prior therapies.
Its targeted mechanism helps to deliver the therapeutic agent directly to cancer cells, minimizing impact on healthy cells to some extent.
Clinical studies have demonstrated its ability to improve outcomes in patients with specific forms of urothelial cancer.
It represents an important advancement in oncology for patients with limited treatment alternatives.
How to Use
1. Padcev is to be administered by a healthcare professional experienced in oncology treatment.
2. The medication is provided as a powder and must be reconstituted with sterile water for injection, then further diluted in an infusion bag.
3. It is administered as an intravenous infusion over a period of 30 minutes.
4. The specific dosage and treatment schedule will be determined by your doctor based on your medical condition, body weight, and response to therapy.
5. Do not attempt to self-administer this medication.
6. Follow all instructions provided by your healthcare team regarding appointments and treatment cycles.
Caution & Warnings
Padcev can cause serious side effects, including peripheral neuropathy, which may manifest as numbness, tingling, or weakness, primarily in the hands or feet. Report any new or worsening nerve problems to your doctor immediately.
Severe skin reactions, including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, have occurred. Monitor for rash and seek immediate medical attention for blistering, peeling skin, or painful sores.
Hyperglycemia (high blood sugar) can occur. Blood glucose levels should be monitored before and during treatment, especially in patients with diabetes or risk factors for diabetes.
Ocular disorders, such as dry eyes, blurry vision, or vision loss, are possible. Eye exams may be recommended before and during treatment.
Interstitial lung disease (ILD) or pneumonitis, a serious and potentially fatal inflammation of the lungs, may occur. Report any new or worsening respiratory symptoms like cough, shortness of breath, or fever.
Padcev can cause harm to an unborn baby. Women of childbearing potential should use effective contraception during treatment and for a specified period after the last dose. Men with female partners of childbearing potential should also use effective contraception.
Consult your doctor about all existing medical conditions, especially diabetes, skin disorders, or vision problems, before starting Padcev.
Inform your doctor about all other medications you are taking, including prescription, over-the-counter drugs, vitamins, and herbal supplements, as they may interact with Padcev.
Ingredients
Active Ingredient: Enfortumab Vedotin 30 mg
Excipients: Trehalose dihydrate, Polysorbate 80, Sodium Citrate, Citric Acid Monohydrate
Product Details
Product Name: Padcev 30 mg Powder for concentrate for solution for infusion
Form: Powder for concentrate for solution for infusion
Strength: 30 mg
Package Size: 1 Vial
Manufacturer: Astellas Pharma
Drug Type: Prescription Medicine
Storage: Refrigerate at 2°C to 8°C (36°F to 46°F), protect from light.
| Gtin | 1811246254 |
|---|---|
| Recommended Sale Price | 4320.75 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | ENFORTUMAB |
| SFDA Reg. No | 1811246254 |
| IBC | 1811246254 |
| Drug Type | Prescription |
| Scientific Name | Enfortumab vedotin |
| Strength | 30 |
| Strength Unit | mg |
| Form | Powder for concentrate for solution for infusion |
| Admin Route | Intravenous |
| Size | 1 |
| Size Unit | vial |
| Package Types | Vial |
| Package Size | 1 vial |
| Storage conditions | Store unopened vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. |
| Refrigerator Storage | Yes |
